RT

Ravi Thadhani

Orthocell Limited | Non-Executive Director
Dr Thadhani has experience in patient care, advancing novel research programs, US regulatory pathways and commercialisation of devices and therapeutics. He served on multiple US FDA advisory committees in the musculoskeletal, cardiovascular and renal sectors providing expert guidance to the FDA and companies regarding the regulatory requirements for approval of medical devices and therapeutics, High-profile healthcare administration roles, most recently professor of medicine at Harvard Medical School and chief academic officer and dean for faculty affairs for Mass General Brigham hospital, research enterprise Expert advisor to multiple global pharmaceutical companies including Sandoz, Shire, Novartis, Celgene, Bayer and Reata on clinical trial design, execution and data monitoring Co-author of more than 300 scientific publications.

Company and Role

Company
Title
Tenure
Since
OCC
Orthocell Limited
  • Non-Executive Director
1yrs, 2mthMar 2023

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
OCC
Orthocell Limited
27/09/23N/AN/A3,000,000N/A